AVR
HEALTHCAREAnteris Technologies Global Corp. Common Stock
AI Insight
What's Moving AVR Today?
No stock-specific AI insight has been generated for AVR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.85$10.56
$10.28
Fundamentals
Market Cap$934M
P/E Ratio—
EPS$-2.22
Dividend Yield—
Dividend / Share—
ROE-59.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding97.3M
AVR News
24 articles- TAVR Changed Valve Replacement; Anteris Says Longer-Living Patients Expose the Next ChallengeYahoo Finance·Jun 15, 2026
- France clearance marks key milestone for Anteris' pivotal PARADIGM TrialProactive Investors·Jun 8, 2026
- Anteris Advances Global PARADIGM Expansion with French Regulatory ClearanceYahoo Finance·Jun 8, 2026
- Anteris Technologies Global Corp plans to issue up to $250 million in common stock through TD Cowen as the underwriter.Bitget·May 23, 2026
- Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn SituationYahoo Finance·May 13, 2026
- Anteris Appoints Susan Knight and Stephen Denaro to its Board of DirectorsYahoo Finance·May 13, 2026
- Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategyProactive Investors·May 13, 2026
- Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation pushProactive Investors·May 12, 2026
- Anteris Technologies Global Corp reports results for the quarter ended March 31 - Earnings SummaryTradingView·May 12, 2026
- Anteris Announces Results for the First Quarter of 2026The Manila Times·May 12, 2026
- Anteris Announces Results for the First Quarter of 2026Caledonian Record·May 12, 2026
- Heart valve firm Anteris raises $320M to drive global DurAVR trialStock Titan·May 12, 2026
- Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advancesProactive Investors·May 7, 2026
- Anteris treats first US patients in DurAVR pivotal trialProactive Investors·May 7, 2026
- Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valveYahoo Finance·May 6, 2026
- Small Cap Watch: Small Ordinaries edges higher as company news flow continuesProactive Investors·May 6, 2026
- Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM TrialYahoo Finance·May 5, 2026
- Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM TrialGlobeNewswire Inc.·Apr 28, 2026
- A new valve, a new playbook: How Anteris is trying to reshape a $10B heart marketProactive Investors·Apr 2, 2026
- Truffle Capital Unveils the First Edition of the Truffle MedTech 10Yahoo Finance·Mar 18, 2026
- Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market StrategyMarketbeat·Mar 12, 2026
- Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen ConferenceMarketbeat·Mar 5, 2026
- Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underwayProactive Investors·Feb 26, 2026
- Anteris Reports 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 26, 2026
All 24 articles loaded
Price Data
Open$9.38
Previous Close$10.28
Day High$10.56
Day Low$9.35
52 Week High$10.56
52 Week Low$2.85
52-Week Range
$2.85$10.56
$10.28
Fundamentals
Market Cap$934M
P/E Ratio—
EPS$-2.22
Dividend Yield—
Dividend / Share—
ROE-59.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding97.3M
About Anteris Technologies Global Corp. Common Stock
Anteris Technologies Global Corp. The company is headquartered in Toowong, Australia.
HEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL INSTRUMENTS & SUPPLIES
CIK—
Composite FIGI—
Share Class FIGI—